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Fat Embolism: What We Have 
Learned from Animal Models
Alan M. Poisner and Agostino Molteni
Abstract
Pulmonary fat embolism may not be diagnosed before unrelated autopsy and 
have little clinical impact or lead to acute lung injury with fulminant fat embolism 
syndrome (FES). The fat may come from various anatomic locations, bone mar-
row being the most common. There is no specific treatment. This review discusses 
animal models that can lead to a better understanding of pathophysiological 
mechanisms underlying this condition and indicates the importance of specific 
cellular constituents. A hypothesis is postulated that there is a vicious cycle involv-
ing oleic acid and angiotensin II (both of which are pulmonary toxicants): oleic acid 
is derived from lipid embolism by pulmonary lipases that are stimulated by angio-
tensin; oleic acid also promotes local generation of angiotensin. The potential role 
of fatty acid receptors and the resolution of this cycle are discussed. Studies show 
there is potential for long-term effects that might not be revealed in the immediate 
post-recovery period. Evidence is reviewed that animals are vulnerable to “second 
hit” effects at a time remote from the initial event. Some beneficial pharmacologi-
cal treatments are described. These include different drugs acting on the renin-
angiotensin system (RAS) that could eventually serve alone or in combination for 
treatment or prevention. Future therapeutic developments are discussed.
Keywords: fat embolism, lung, renin-angiotensin system, rat, drug treatment,  
time course, second hit, animal model, histopathology, triolein
1. Introduction
Fat embolism was described many years ago. As early as 1862 [1] as cited in a 
1971 review by Herndon [2], there was a report of fat droplets in the lungs of a 
factory worker who died after a crushing injury to his chest and abdomen. The 
term “fat embolism” itself includes many types of conditions in which some type of 
fatty substance is embedded in a tissue remote from its source. The most common 
source is from bone marrow that escapes into the venous system after trauma and 
surgery, including bone marrow reaming [3], liposuction [4], fat injection [5], or 
necrosis, as in sickle cell disease resulting in acute chest syndrome [6]. There are 
also some forms that do not result from trauma or surgery [7]. What distinguishes 
fat embolism from other strictly physical forms is that in addition to the physical 
obstruction of the vasculature that can accompany the lodging in capillaries, there 
are also biochemical consequences in response to the ensuing lipid metabolism and 
also pathological processes that are triggered intracellularly after engulfing of the 
fat. The most common target for embolic fat is the lung, but other significant sites 
include the skin, the eyes, and the brain with subsequent clinical sequelae [8].
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The clinical consequences of fat embolism have been reviewed many times over 
the years, including this year [8]. The symptoms may be so minor that they can be 
missed [9] or appear after an interval as much as 48–96 h leading to acute respiratory 
distress syndrome [ARDS] with mortality ranging from 10 to 15% [8, 9]. This has 
been called fat embolism syndrome [FES], sometimes with accompanying CNS [10], 
ocular [11] or dermal pathology [12]. Treatment has been supportive: recent reviews 
indicate that there is no specific treatment available [8, 12]. Although a patent foramen 
ovale is sometimes a contributing factor in systemic consequences of fat embolism, for 
instance, in the eye and the brain, this is clearly not the case in most cases of FES.
Therefore, there have been many attempts to produce an animal model in 
hopes of delineating the underlying pathophysiology, so specific treatment could 
be obtained. Animal models have included rats [13], mice [14], rabbits [15], dogs 
[16], sheep [17], pigs [18], and even baboons [19]. While a majority of these studies 
have focused on orthopedic-related problems [20], it would help to examine a wide 
variety of initiating causes in order to find some common underlying pathophysi-
ological processes. This might lead to more specific methods to treat or prevent 
this condition before the array of downstream mediators, such as peptides and 
cytokines, have been activated. The aim of this chapter is to review what has been 
learned from the diverse animal studies and provide one unifying concept based on 
the role of the renin-angiotensin system as a key player in fat embolism syndrome.
2. Studies on bone
2.1 Reaming and nailing
In order to simulate in animals the surgical procedure used in humans that can lead 
to fat embolism syndrome, a number of different animals have been subjected to nail-
ing, with or without reaming [3]. It was concluded that more experiments should be 
carried out in order to determine the optimal method to perform the surgical proce-
dures. It was also made clear that other factors influence the development of systemic 
and pulmonary complications [3]. A comprehensive review of animal studies of 
intramedullary nailing concludes that events that may predispose to adverse postsur-
gical impact are important and that studies should take these into consideration [20].
2.2 Bone marrow fat and non-bone marrow fat injection
A number of studies have been carried out with infusions of bone marrow 
extracts or non-marrow fat. An excellent review on animal studies of acute lung 
injury, which includes oleic acid as a possible model for fat embolism, indicates that 
this model does not really mimic the clinical syndrome of FES [21]. In addition, a 
study on rats showed that the intravenous injection of oleic acid, unlike neutral fat, 
did not result in the deposition of fat droplets [22].
A study on liposuction in rats performed on the lateral flank and the abdomen 
showed that fat was delivered to the lungs and other organs [23]. Some animal stud-
ies on fat embolism have utilized subcutaneous fat [22]. This has clinical parallels in 
which subcutaneous injection in humans has caused fatal fat embolism [24].
3. Triolein: the prototype fat embolism model
Since neutral fat seems to be the main culprit in fat embolism and is the major 
fat in bone marrow and subcutaneous tissues [25] and pulmonary emboli [26], the 
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neutral fat triolein has been the most studied in vivo and in vitro. Although a number 
species have been studied, the rat has been studied the most, particularly after the 
groundbreaking work of L.F. Peltier [27–29]. He studied fat embolism in cats and dogs 
but mostly in rats. This work included description of the fat content of bone marrow 
and body fat, distribution of labeled triolein after i.v. injection, changes in blood and 
lung lipase after embolism, kinetics of the phenomena, and other studies in animals 
and patients. Some advantages of triolein studies in the rat are described below.
3.1 Advantages of triolein and our model
Triolein [glyceryl trioleate] is available as a pure liquid that can be injected i.v. 
directly or after emulsification. We have used conscious animals since there are 
studies indicating that anesthesia alters pulmonary response to fat embolism [30]. 
Although oleic acid is a well-known pulmonary toxicant, as mentioned above, it is 
not a suitable model for fat embolism syndrome. The conversion of triolein to oleic 
acid by pulmonary tissue [31] provides support for the proposed sequence of events 
postulated by Szabo [32].
3.2 Findings in the conscious rat triolein model of fat embolism
3.2.1 Time course of changes in pulmonary histopathology
Initial histopathological studies on the time course of triolein-induced lung injury 
revealed changes as early as 12–24 h which included thickening of the arterial and arte-
riolar media, mostly with myofibroblasts and inflammation in the septa with increased 
numbers of macrophages. Bronchial alveolar lavage (BAL) at 24 h revealed macro-
phages, some of which showed inflammatory response and fat droplets. Inflammation 
was still present at 11 days with damage to the bronchial epithelium [33].
Later studies at 3 and 6 weeks showed that after the first peak [48–72 h] and 
partial resolution, there were persistent and progressive inflammatory and fibrotic 
changes up to 6 weeks after injection of triolein [34]. This was associated with an 
increase in angiotensin peptides [34], implicating the renin-angiotensin system 
(RAS) in the pathophysiology (see below).
In order to determine if the lungs of the animals at this late time would be 
especially sensitive to another pulmonary insult, the animals were exposed to the 
known pulmonary toxicant lipopolysaccharide (LPS) at 6 weeks. Forty-eight hours 
after this “second hit,” there was an enhanced histopathological response in animals 
previously exposed to triolein [35].
These animals had apparently recovered completely at 6 weeks from the initial 
triolein treatment as judged by normal weight gain and no observable behavioral 
changes. It was concluded that the compromised lungs seen at 6 weeks exposed the 
vulnerability of animals long after they had seemingly recovered. The histopathol-
ogy was also found at 10 weeks along with the persistence of some small fat droplets 
extracellularly and also in some macrophages [36] [see below].
4. Role of the renin-angiotensin system
Because the renin-angiotensin system (RAS) has been implicated in a wide 
variety of other pulmonary experimental models [37, 38], we examined whether this 
might hold true for the fat embolism model, and in fact it has since been proposed 
that most forms of pulmonary inflammatory disease involve the RAS, but that list 
did not include fat embolism [39]. We found that three different agents that interfere 
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with the RAS were found to ameliorate the pulmonary damage found at 48 h after 
triolein: the angiotensin-converting enzyme (ACE) inhibitor captopril [40], the 
angiotensin II type 1 receptor blocker losartan [40], and the renin inhibitor aliskiren 
[41]. In addition, it was found that the remaining inflammation that was evident 
at 6 weeks was also reduced when losartan was given at this late time period and 
the animals were sacrificed 4 weeks later (10 weeks after the initial exposure to 
triolein) [36]. These results suggest that angiotensin II, produced by the angiotensin-
converting enzyme (ACE) and acting on the type 1 receptor, is a critical pathological 
actor in the pathophysiology of fat embolism both acutely and after a substantial 
delay. However, it does not indicate precisely where this peptide comes from or how 
it is formed. All of the components of the RAS have been found or implicated in the 
lung [42]. Possible players in its formation prior to ACE activity could be renin or 
prorenin that is catalytically active when bound to its receptor [43]. Furthermore, 
other angiotensin peptides with anti-inflammatory and antifibrotic activity could 
be counterbalancing forces as well. Most of the extrarenal renin is in the form of 
prorenin which also has angiotensin-independent pro-fibrotic properties [44–46].
There are many possible cells that could provide components of the RAS to the 
pulmonary inflammatory process. These include mast cells [47], fibroblasts [48], 
myofibroblasts [49], vascular smooth muscle [50], and macrophages [51].
There are a number of studies suggesting a critical role of mast cells in RAS media-
tion of pulmonary pathology [52–54]. It has been suggested that activated macrophages 
stimulate pulmonary mast cells to release renin and the subsequent production of 
angiotensin peptides leads to adverse reactions [54]. Mast cells have also been shown 
to stimulate fibroblasts in the lung [55]. Triolein increases mast cell accumulation in a 
chronic model, and their appearance is reduced by losartan [56], and aliskiren reduces 
the triolein-induced increase of mast cell number found at 48 hours [57]. Another mast 
cell enzyme that has been implicated in angiotensin formation is chymase [58, 59]. It 
is known that there is mast cell heterogeneity in rodents and humans [60–62], and in 
humans this includes the presence of renin and its localization within the lungs [62].
In support of the importance of renin/prorenin in fat embolism, we have found 
an increase in renin staining at 48 hours (Figure 1) and 6 weeks after triolein-
induced fat embolism [63, 64].
5. The nexus of fat metabolism and action and the RAS in the lungs
It has long been speculated that angiotensin II, acting through the type 1 recep-
tor, was a primary inflammatory molecule [65]. In recent years it has become appar-
ent that angiotensin II acting through its type 2 receptor has anti-inflammatory 
Figure 1. 
Triolein increases lung renin staining: enhanced by captopril and losartan [64].
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actions [66] and the literature on similar anti-inflammatory actions through the 
Ang 1-7/Mas receptor have exploded [67]. It appears that the pathophysiological 
state of the lungs is a balance between the pro-inflammatory, pro-fibrotic arm of 
the RAS, and the counterbalancing peptide/receptor activity. It is not surprising 
that Ang 1-7 has been found to have beneficial effects in the lung [68, 69].
How is the renin-angiotensin system activated in fat embolism, and what is the 
connection to fat (neutral and fatty acids)? One suggestion based on the work of 
Gonzalez et al. [52, 54, 70] would have a sequence of fat engulfment by macro-
phages, and subsequently the activated cells would release monocyte chemoattrac-
tant-1 (MCP-1) that stimulates mast cells (nearby or remote) to release renin and 
angiotensin generation. However, activated macrophages themselves might act in 
an autocrine or paracrine manner to release renin, and there is evidence for intra-
crine generation of angiotensin as well [71, 72]. There may be intracrine actions of 
angiotensin as well on mitochondria and nuclei.
If the RAS is involved in many aspects, including initiating a cascade of down-
stream malevolent molecules, where does the fat enter the picture? As a host of 
review articles have discussed, there is a strictly mechanical phase during which 
the fat emboli obstruct capillaries and cause a short-term hypoxia. It is known that 
hypoxia itself can lead to pulmonary dysfunction and this can be offset experimen-
tally by angiotensin-converting enzyme inhibition (ACEI) [73] and is associated 
with an increase in circulating angiotensin peptides [74].
It is clear from the vast literature on metabolism of fat after embolism that most 
of the lipolysis of neutral fat (mostly triolein) takes place near pulmonary endothelial 
cells that convert triolein to the toxic oleic acid by lipoprotein lipase. It is now known 
that oleic acid, although not thought to enter cells [21], can activate its own fatty acid 
receptor (FFAR/GPR120) which can evoke pulmonary edema [75, 76]. Interestingly, 
the toxic effects of oleic acid (including pulmonary edema) are antagonized by the 
non-specific angiotensin receptor blocker 1-sarcosine, 8-isoleucine angiotensin II 
[77]. This implicates angiotensin II in another way as a key mediatory in pulmonary 
pathology. It has also been reported that oleic acid and angiotensin II are synergistic 
in promoting a mitogenic effect in vascular smooth muscle [78]. Oleic acid emanating 
from triolein thus is a co-conspirator in evoking pulmonary (and probably other) 
pathological conditions, such as cerebral fat embolism [10, 79]. Pathways that oleic 
acid and angiotensin utilize in producing pathological responses are listed in Figure 2.
5.1 A vicious cycle of oleic acid and angiotensin II in fat embolism syndrome
To explain how the sudden appearance of fat in the pulmonary circulation can 
sometimes produce an acute respiratory distress syndrome and why the neutral fat 
(primarily triolein) has the potential to lead to longer-term pulmonary damage, 
the following hypothesis is presented (Figure 3). The initial mechanical phase 
of vascular obstruction which leads to hypoxia is known to be ameliorated by the 
angiotensin receptor blocker losartan [80].
The delayed metabolic phase is related to breakdown of the most abundant fat 
in emboli which is hydrolyzed by several triglyceride lipases to yield oleic acid. 
These include endothelial lipase (EL) and lipoprotein lipase (LIPL) [81, 82] as well 
as macrophage LIPL [83]. This in turn leads to the evolution of free fatty acids, 
mainly oleic acid, which is toxic to the endothelium and is released in part in close 
proximity to endothelial cells. Macrophages become activated after phagocytosing 
lipid particles which leads to paracrine and endocrine activation of mast cells that 
induces angiotensin generation [54].
In addition, there is generation of angiotensin and oleic acid intracellularly in 
macrophages (both of which are toxic to mitochondria [84, 85]). Since oleic acid 
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has been shown to increase angiotensin II release from several cell types [86] and 
angiotensin increases the expression of various lipases [87], the cycle continues 
until rescue mechanisms ensue (Figure 4). It should be noted that losartan and 
perindopril, ACE inhibitors, prevent fatty acid-induced endothelial dysfunction 
Figure 2. 
Fat embolism pathways.
Figure 3. 
Oleic acid-angiotensin cycle: OA ↑ Ang release; Ang ↑ triolein lipolysis.
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in humans in response to elevated blood lipids [88]. Furthermore, oleic acid also 
increases serum renin and angiotensin, and its effects on pulmonary edema are 
blocked by blocked by an ACE inhibitor [89].
Most cases of fat embolism do not lead to fat embolism syndrome because the 
amount of the fat is not of sufficient volume or due to the countervailing mecha-
nisms. These include actions of angiotensin II on AT2 receptors, metabolism of 
angiotensin II by angiotensinases, anti-inflammatory actions of its metabolite, 
angiotensin (1-7), metabolism of oleic acid, clearance of lipids via vascular or 
lymphatic channels, and ultimately renal excretion (Figure 4).
6. Conclusions and prospects
It is proposed that elements of the renin-angiotensin system are central mediators 
of tissue injury after fat embolism. Although hypoxia due to capillary blockage is a 
contributing factor to lung injury, oleic acid liberated from triolein hydrolysis is a 
crucial step, and it also is associated with angiotensin biology. Angiotensin II through 
its type 1 receptor is the major offender. Our animal experiments have indicated that 
three US Food and Drug Administration (FDA)-approved drugs (captopril, losartan, 
and aliskiren) may have protective value as mentioned above. However, in a clinical 
setting where trauma or surgery may be involved, stability of blood pressure may be 
compromised by these agents. Therefore, it is suggested that some of these types of 
agents (or a combination) could be administered by inhalation.
Rather than antagonizing the angiotensin II generation with ACE or renin 
inhibitors or angiotensin type 1 activity with antagonists (ARBS), it may be possible 
to treat/prevent fat embolism injury by stimulating the angiotensin type 2 receptor 
(AT2) with peptide or non-peptide agonists such as C21 [90]. Another possible ther-
apeutic approach would be to activate the ACE2/angiotensin [1-7]/MAS axis with a 
peptide or non-peptide agonist, such as AVE0091 [68]. A more promising avenue for 
preventing or treating fat embolism will more likely be satisfactory if multiple points 
of the early stages of the pathophysiology are attacked simultaneously. That would 
include not only the RAS drugs mentioned above but also possibly mast stabilizers 
that can be given by the inhalation route and some of the newly described drugs that 
act on the FFA receptors mentioned above. In addition it is possible that some of the 
newer triglyceride lipase inhibitors could be of value as preventive treatment.
Although the emphasis in this review is on pulmonary fat embolism, there is 
ample evidence from clinical experience and animal experiments that the eyes, 
particularly the retina, are frequently targets of fat embolism. Both triolein and 
oleic acid have been implicated in ocular pathology [91, 92], and the RAS is thought 
to be an important mediating system in many ocular diseases [93].
Figure 4. 
Repair mechanisms for fat embolism.
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Another non-pulmonary target of fat embolism in clinical FES is the brain, and 
cerebral fat embolism can be fatal [94]. Although a patent foramen ovale is some-
times an important factor in cerebral fat embolism, this is clearly not the case in 
many instances, and animal models have not provided any new insights of cardiac 
defects being major players. In a rat model, there is some evidence that cerebral fat 
embolism may involve a serine protease [79] and maybe this could be related to a 
non-renin generation of angiotensin by a chymase-like enzyme. The RAS is now 
believed to be important for much CNS pathology [95].
There now is reason to be optimistic that the next comprehensive review of fat 
embolism syndrome will describe some new available therapeutic options based on 
animal experiments. This reinforces the goal of animal experiments to delineate the 
pathophysiological mechanisms underlying human disease, so specific treatment 
can be implemented.
Acknowledgements
We acknowledge the support of Dr. Gary Salzman, M.D., and the Mary Catherine 
Geldmacher Foundation of St. Louis, MO, the graphical help from Dr. Doud Arif, 
and the inspiration to begin this research from the late Dr. Federico Adler.
9Fat Embolism: What We Have Learned from Animal Models
DOI: http://dx.doi.org/10.5772/intechopen.85178
References
[1] Zenker FA. Beiträge zur normalen 
und pathologischen Anatomie der 
Lungen. Braunsnsdorf: Dresden; 1862
[2] Herndon JH, Riseborough EJ, Fischer 
JE. Fat embolism: A review of current 
concepts. The Journal of Trauma. 
1971;11(8):673-680
[3] Hildebrand F, Andruszkow H, 
Barkatali BM, Pfeifer R, Lichte P, 
Kobbe P, et al. Animal models to 
assess the local and systemic effects 
of nailing: Review of the literature 
and considerations for future studies. 
Journal of Trauma and Acute Care 
Surgery. 2014;76(6):1495-1506
[4] Cantu CA, Pavlisko EN. Liposuction-
induced fat embolism syndrome: 
A brief review and postmortem 
diagnostic approach. Archives of 
Pathology & Laboratory Medicine. 
2018;142(7):871-875
[5] Cardenas-Camarena L, Bayter 
JE, Aguirre-Serrano H, Cuenca-
Pardo J. Deaths caused by gluteal 
lipoinjection: What are we doing wrong? 
Plastic and Reconstructive Surgery. 
2015;136(1):58-66
[6] Vichinsky E, Williams R, Das 
M, Earles AN, Lewis N, Adler A, 
et al. Pulmonary fat embolism: A 
distinct cause of severe acute chest 
syndrome in sickle cell anemia. Blood. 
1994;83(11):3107-3112
[7] Schulz F, Trubner K, Hildebrand 
E. Fatal fat embolism in acute hepatic 
necrosis with associated fatty liver. The 
American Journal of Forensic Medicine 
and Pathology. 1996;17(3):264-268
[8] Fukumoto LE, Fukumoto 
KD. Fat embolism syndrome. The 
Nursing Clinics of North America. 
2018;53(3):335-347
[9] Eriksson EA, Pellegrini DC, 
Vanderkolk WE, Minshall CT, 
Fakhry SM, Cohle SD. Incidence of 
pulmonary fat embolism at autopsy: 
An undiagnosed epidemic. Journal of 
Trauma. 2011;71(2):312-315
[10] Dines DE, Burgher LW, Okazaki 
H. The clinical and pathologic 
correlation of fat embolism 
syndrome. Mayo Clinic Proceedings. 
1975;50(7):407-411
[11] Spirn MJ, Biousse V. Retinal fat 
emboli. The Journal of Emergency 
Medicine. 2005;29(3):339-340
[12] Shaikh N. Emergency management 
of fat embolism syndrome. Journal 
of Emergencies, Trauma, and Shock. 
2009;2(1):29-33
[13] Inoue H, Hanagama M, Kamiya 
M, Shinone K, Nata M. Experimental 
pulmonary fat embolism induced 
by injection of triolein in rats. 
Legal Medicine. 2008;10:26-30
[14] Zhang Y, Tian K, Wang Y, Zhang 
R, Shang J, Jiang W, et al. The effects 
of aquaporin-1 in pulmonary edema 
induced by fat embolism syndrome. 
International Journal of Molecular 
Sciences. 2016;17(7):1183
[15] Woo OH, Yong HS, Oh YW, Shin 
BK, Kim HK, Kang EY. Experimental 
pulmonary fat embolism: Computed 
tomography and pathologic 
findings of the sequential changes. 
Journal of Korean Medical Science. 
2008;23(4):691-699
[16] Byrick RJ, Mullen JB, Mazer CD, 
Guest CB. Transpulmonary systemic 
fat embolism. Studies in mongrel dogs 
after cemented arthroplasty. American 
Journal of Respiratory and Critical Care 
Medicine. 1994;150:1416-1422
[17] Aebli N, Krebs J, Davis G, Walton 
M, Williams MJ, Theis JC. Fat embolism 
and acute hypotension during 
10
Embolic Diseases - Evolving Diagnostic and Management Approaches
vertebroplasty: An experimental 
study in sheep. Spine [Phila Pa 1976 ]. 
2002;27(5):460-466
[18] Wang AZ, Zhou M, Jiang W, Zhang 
WX. The differences between venous air 
embolism and fat embolism in routine 
intraoperative monitoring methods, 
transesophageal echocardiography, 
and fatal volume in pigs. The Journal of 
Trauma. 2008;65(2):416-423
[19] Kropfl A, Davies J, Berger U, Hertz 
H, Schlag G. Intramedullary pressure 
and bone marrow fat extravasation in 
reamed and unreamed femoral nailing. 
Journal of Orthopaedic Research. 
1999;17(2):261-268
[20] Pape HC, Hildebrand F, Krettek C, 
Green J, Giannoudis PV. Experimental 
background—Review of animal studies. 
Injury. 2006;37(Suppl 4):S25-S38
[21] Matute-Bello G, Frevert CW, Martin 
TR. Animal models of acute lung injury. 
American Journal of Physiology. Lung 
Cellular and Molecular Physiology. 
2008;295(3):L379-L399
[22] Takada M, Chiba S, Nagai T, Takeshita 
H, Kanno S, Ikawa T, et al. Inflammatory 
responses to neutral fat and fatty acids 
in multiple organs in a rat model of fat 
embolism syndrome. Forensic Science 
International. 2015;254:126-132
[23] Lim KR, Cho JM, Yoon CM, Lee KC, 
Lee SY, Ju MH. Correlation between 
the time elapsed after liposuction and 
the risk of fat embolism: An animal 
model. Archives of Plastic Surgery. 
2018;45(1):14-22
[24] Mofid MM, Teitelbaum S, Suissa 
D, Ramirez-Montanana A, Astarita 
DC, Mendieta C, et al. Report on 
mortality from gluteal fat grafting: 
Recommendations from the ASERF 
Task Force. Aesthetic Surgery Journal. 
2017;37(7):796-806
[25] Peltier LF, Wheller DH, BOYD HM, 
Scott JR. Fat embolism. II. The chemical 
composition of fat obtained from 
human long bones and subcutaneous 
tissue. Surgery. 1956;40(4):661-664
[26] Sherr S, Montemurno R, Raffer 
P. Lipids of recovered pulmonary fat 
emboli following trauma. The Journal of 
Trauma. 1974;14(3):242-246
[27] Peltier LF. Fat embolism following 
intramedullary nailing; report of a 
fatality. Surgery. 1952;32(4):719-722
[28] Peltier LF. Fat embolism: 
A pulmonary disease. Surgery. 
1967;62(4):756-758
[29] Peltier LF. Fat embolism. 
A perspective. Clinical 
Orthopaedics and Related Research. 
1988;232:263-270
[30] Wang AZ, Ma QX, Zhao HJ, Zhou 
QH, Jiang W, Sun JZ. A comparative 
study of the mortality rate of rats 
receiving a half lethal dose of 
fat intravenously: Under general 
anaesthesia versus under spinal 
anaesthesia. Injury. 2012;43(3):311-314
[31] Compton SK, Hamosh M, Hamosh 
P. Hydrolysis of triglycerides in the 
isolated perfused rat lung. Lipids. 
1982;17:696-702
[32] Szabo G, Magyar Z, Reffy A. The 
role of free fatty acids in pulmonary fat 
embolism. Injury. 1977;8(4):278-283
[33] McIff TE, Poisner AM, Herndon B, 
Lankachandra K, Schutt S, Haileselassie 
B, et al. Fat embolism: Evolution of 
histopathological changes in the rat 
lung. Journal of Orthopaedic Research. 
2010;28(2):191-197
[34] Poisner AM, Adler F, Uhal B, McIff 
TE, Schroeppel JP, Mehrer A, et al. 
Persistent and progressive pulmonary 
fibrotic changes in a model of fat 
embolism. Journal of Trauma and Acute 
Care Surgery. 2012;72(4):992-998
11
Fat Embolism: What We Have Learned from Animal Models
DOI: http://dx.doi.org/10.5772/intechopen.85178
[35] Poisner AM, Herndon B, 
Lankachandra K, Likhitsup A, Al 
Hariri A, Kesh S, et al. Fat embolism 
sensitizes rats to a “second hit” with 
lipopolysaccharide: An animal model of 
pulmonary fibrosis. Journal of Trauma 
and Acute Care Surgery. 2015;78:552-557
[36] Poisner A, Herndon B, Bass D, 
Fletcher A, Jain A, England JP, et al. 
Evidence for angiotensin mediation of 
the late histopathological effects of fat 
embolism: Protection by losartan in a 
rat model. Experimental Lung Research. 
2019;44:363-367
[37] Molteni A, Moulder JE, Cohen 
EF, Ward WF, Fish BL, Taylor JM, 
et al. Control of radiation-induced 
pneumopathy and lung fibrosis by 
angiotensin-converting enzyme 
inhibitors and an angiotensin II type 
1 receptor blocker. International 
Journal of Radiation Biology. 
2000;76(4):523-532
[38] Molteni A, Ward WF, 
Ts’ao CH, Solliday NH, Dunne 
M. Monocrotaline-induced pulmonary 
fibrosis in rats: Amelioration 
by captopril and penicillamine. 
Proceedings of the Society for 
Experimental Biology and Medicine. 
1985;180(1):112-120
[39] Tan WSD, Liao W, Zhou S, Mei 
D, Wong WF. Targeting the renin-
angiotensin system as novel therapeutic 
strategy x for pulmonary diseases. 
Current Opinion in Pharmacology. 
2018;40:9-17
[40] McIff TE, Poisner AM, Herndon 
B, Lankachandra K, Molteni A, Adler 
F. Mitigating effects of captopril and 
losartan on lung histopathology in a rat 
model of fat embolism. The Journal of 
Trauma. 2011;70:1186-1191
[41] Fletcher A, Molteni A, 
Ponnapureddy R, Patel C, Pluym 
M, Poisner AM. The renin inhibitor 
aliskiren protects rat lungs from 
the histopathological effects of fat 
embolism. Journal of Trauma and Acute 
Care Surgery. 2017;82:338-344
[42] Marshall RP. The pulmonary 
renin-angiotensin system. 
Current Pharmaceutical Design. 
2003;9(9):715-722
[43] Ahmed BA, Seda O, Lavoie JL. 
[Pro]renin receptor as a new drug 
target. Current Pharmaceutical Design. 
2011;17(33):3611-3621
[44] Sealey JE, Rubattu S. Prorenin and 
renin as separate mediators of tissue and 
circulating systems. American Journal 
of Hypertension. 1989;2:358-366
[45] Sihn G, Rousselle A, Vilianovitch 
L, Burckle C, Bader M. Physiology 
of the [pro]renin receptor: Wnt 
of change? Kidney International. 
2010;78(3):246-256
[46] Hennrikus M, Gonzalez AA, 
Prieto MC. The prorenin receptor in 
the cardiovascular system and beyond. 
American Journal of Physiology. 
Heart and Circulatory Physiology. 
2018;314(2):H139-H145
[47] Silver RB, Reid AC, Mackins CJ, 
Askwith T, Schaefer U, Herzlinger 
D, et al. Mast cells: A unique 
source of renin. Proceedings of 
the National Academy of Sciences 
of the United States of America. 
2004;101(37):13607-13612
[48] Dostal DE, Rothblum KN, Conrad 
KM, Cooper GR, Baker KM. Detection 
of angiotensin I and II in cultured 
rat cardiac myocytes and fibroblasts. 
The American Journal of Physiology. 
1992;263:C851-C863
[49] Katwa LC, Campbell SE, 
Tyagi SC, Lee SJ, Cicila GT, Weber 
KT. Cultured myofibroblasts generate 
angiotensin peptides de novo. Journal 
of Molecular and Cellular Cardiology. 
1997;29:1375-1386
Embolic Diseases - Evolving Diagnostic and Management Approaches
12
[50] Iwai N, Matsunaga M, Kita T, Tei 
M, Kawai C. Regulation of renin-like 
enzyme in cultured human vascular 
smooth muscle cells. Japanese 
Circulation Journal. 1988;52:1338-1345
[51] Iwai N, Inagami T, Ohmichi N, 
Kinoshita M. Renin is expressed in 
rat macrophage/monocyte cells. 
Hypertension. 1996;27:399-403
[52] Gonzalez NC, Allen J, Schmidt EJ, 
Casillan AJ, Orth T, Wood JG. Role of 
the renin-angiotensin system in the 
systemic microvascular inflammation 
of alveolar hypoxia. American Journal 
of Physiology. Heart and Circulatory 
Physiology. 2007;292:H2285-H2294
[53] Veerappan A, O’Connor NJ, Brazin 
J, Reid AC, Jung A, McGee D, et al. 
Mast cells: A pivotal role in pulmonary 
fibrosis. DNA and Cell Biology. 
2013;32(4):206-218
[54] Chao J, Blanco G, Wood JG, 
Gonzalez NC. Renin released from 
mast cells activated by circulating 
MCP-1 initiates the microvascular 
phase of the systemic inflammation 
of alveolar hypoxia. American Journal 
of Physiology. Heart and Circulatory 
Physiology. 2011;301(6):H2264-H2270
[55] Garbuzenko E, Berkman N, 
Puxeddu I, Kramer M, Nagler A, 
Levi-Schaffer F. Mast cells induce 
activation of human lung fibroblasts 
in vitro. Experimental Lung Research. 
2004;30:705-721
[56] Poisner AM, Hamidpour S, Ho A, 
Skaria P, Fletcher A, Simon S, et al. 
Losartan blocks the recruitment of mast 
cells in the lungs of rats subjected to 
fat embolism with or without a second 
hit with LPS. The FASEB Journal. 
2016;30:700.2
[57] Kesh S, Fletcher A, Voelker P, 
Guidos P, Poisner A, Tylski E, et al. 
Aliskiren, a direct renin inhibitor, 
reduces mast cell accumulation in 
lungs of rats after fat embolism. Q JM: 
An International Journal of Medicine. 
2016;109(Suppl 1):S48
[58] Reilly CF, Tewksbury DA, Schechter 
NM, Travis J. Rapid conversion of 
angiotensin I to angiotensin II by 
neutrophil and mast cell proteinases. 
The Journal of Biological Chemistry. 
1982;257:8619-8622
[59] Hultsch T, Ennis MF, Heidtmann 
HH. The role of chymase in ionophore-
induced histamine release from human 
pulmonary mast cells. Advances in 
Experimental Medicine and Biology. 
1988;240:133-136
[60] Tainsh KR, Pearce FL. Mast cell 
heterogeneity: Evidence that mast cells 
isolated from various connective tissue 
locations in the rat display markedly 
graded phenotypes. International 
Archives of Allergy and Immunology. 
1992;98(1):26-34
[61] Irani AM, Schwartz LB. Mast 
cell heterogeneity. Clinical 
and Experimental Allergy. 
1989;19(2):143-155
[62] Andersson CK, Mori M, Bjermer 
L, Lofdahl CG, Erjefalt JS. Novel 
site-specific mast cell subpopulations 
in the human lung. Thorax. 
2009;64(4):297-305
[63] Poisner A, Herndon B, Al Hariri 
A, Qin C, Quinn T. Renin as a mediator 
of pulmonary damage caused by fat 
embolism and LPS. The FASEB Journal. 
2013;27(1 Supplement):lb444
[64] Hamidpour S, Poisner A, Molteni 
A, Al-Husseinawi A, Colson J, Samir 
H, et al. Increased staining for renin/
prorenin in the lungs in a rat model of 
fat embolism is enhanced by captopril 
and losartan which ameliorate the 
pulmonary damage. American Journal 
of Respiratory and Critical Care 
Medicine. 2018;197:A1859
[65] Das UN. Is angiotensin-II an 
endogenous pro-inflammatory 
13
Fat Embolism: What We Have Learned from Animal Models
DOI: http://dx.doi.org/10.5772/intechopen.85178
molecule? Medical Science Monitor. 
2005;11(5):RA155-RA162
[66] Karnik SS, Unal H, Kemp JR, 
Tirupula KC, Eguchi S, Vanderheyden 
PM, et al. Angiotensin receptors: 
Interpreters of pathophysiological 
angiotensinergic stimuli. 
Pharmacological Reviews. 
2015;67(4):754-819
[67] Gironacci MM. Angiotensin-[1-7]: 
Beyond its central effects on blood 
pressure. Therapeutic Advances 
in Cardiovascular Disease. 
2015;9(4):209-216
[68] Klein N, Gembardt F, Supe S, 
Kaestle SM, Nickles H, Erfinanda L, 
et al. Angiotensin-[1-7] protects from 
experimental acute lung injury. Critical 
Care Medicine. 2013;41(11):e334-e343
[69] Uhal BD, Nguyen H, Dang M, 
Gopallawa I, Jiang J, Dang V, et al. 
Abrogation of ER stress-induced 
apoptosis of alveolar epithelial cells by 
angiotensin 1-7. American Journal of 
Physiology-Lung Cellular and Molecular 
Physiology. 2013;305(1):L33-L41
[70] Gonzalez NC, Wood JG. Alveolar 
hypoxia-induced systemic 
inflammation: What low PO[2] does and 
does not do. Advances in Experimental 
Medicine and Biology. 2010;662:27-32
[71] Dezso B, Nielsen AH, Poulsen 
K. Identification of renin in resident 
alveolar macrophages and monocytes: 
HPLC and immunohistochemical stu. 
Journal of Cell Science. 1988;91(Pt 
1):155-159
[72] Chao J, Wood JG, Gonzalez 
NC. Alveolar hypoxia, alveolar 
macrophages, and systemic 
inflammation. Respiratory Research. 
2009;10:54
[73] Zakheim RM, Mattioli L, Molteni 
A, Mullis KB, Bartley J. Prevention 
of pulmonary vascular changes of 
chronic alveolar hypoxia by inhibition 
of angiotensin I-converting enzyme 
in the rat. Laboratory Investigation. 
1975;33(1):57-61
[74] Zakheim RM, Molteni A, Mattioli 
L, Park M. Plasma angiotensin II levels 
in hypoxic and hypovolemic stress 
in unanesthetized rabbits. Journal of 
Applied Physiology. 1976;41(4):462-465
[75] Mizuta K, Zhang Y, Mizuta F, 
Hoshijima H, Shiga T, Masaki E, et al. 
Novel identification of the free fatty 
acid receptor FFAR1 that promotes 
contraction in airway smooth muscle. 
American Journal of Physiology. Lung 
Cellular and Molecular Physiology. 
2015;309(9):L970-L982
[76] Rohwedder A, Zhang Q , Rudge SA, 
Wakelam MJ. Lipid droplet formation 
in response to oleic acid in Huh-7 cells 
is mediated by the fatty acid receptor 
FFAR4. Journal of Cell Science. 
2014;127(Pt 14):3104-3115
[77] Yukioka T, Yukioka N, Aulick 
LH, Goodwin CW, Mason AD Jr, 
Sugimoto T, et al. Evaluation of 
[1-sarcosine, 8-isoleucine] angiotensin 
II as a therapeutic agent for oleic acid-
induced pulmonary edema. Surgery. 
1986;99(2):235-244
[78] Lu G, Meier KE, Jaffa AA, 
Rosenzweig SA, Egan BM. Oleic acid 
and angiotensin II induce a synergistic 
mitogenic response in vascular 
smooth muscle cells. Hypertension. 
1998;31(4):978-985
[79] Xiong L, Sun L, Liu S, Zhu X, 
Teng Z, Yan J. The protective roles of 
urinary trypsin inhibitor in brain injury 
following fat embolism syndrome 
in a rat model. Cell Transplantation. 
2018;963689718814766:1-9
[80] Kiely DG, Cargill RI, Lipworth 
BJ. Acute hypoxic pulmonary 
vasoconstriction in man is attenuated 
by type I angiotensin II receptor 
Embolic Diseases - Evolving Diagnostic and Management Approaches
14
blockade. Cardiovascular Research. 
1995;30:875-880
[81] Coonrod JD, Karathanasis P, Lin 
R. Lipoprotein lipase: A source of free 
fatty acids in bronchoalveolar lining 
fluid. Journal of Laboratory and Clinical 
Medicine. 1989;113(4):449-457
[82] Gal S, Bassett DJ, Hamosh M, 
Hamosh P. Triacylglycerol hyrolysis 
in the isolated, perfused rat lung. 
Biochimica et Biophysica Acta. 
1982;713:222-229
[83] Okabe TF, Yorifuji HF, Murase TF, 
Takaku F. Pulmonary macrophage: 
A major source of lipoprotein 
lipase in the lung. Biochemical and 
Biophysical Research Communications. 
1984;125:273-278
[84] Re RN, Cook JL. The mitochondrial 
component of intracrine action. 
American Journal of Physiology. 
Heart and Circulatory Physiology. 
2010;299(3):H577-H583
[85] Hirabara SM, Silveira LR, Alberici 
LC, Leandro CV, Lambertucci RH, 
Polimeno GC, et al. Acute effect of fatty 
acids on metabolism and mitochondrial 
coupling in skeletal muscle. Biochimica 
et Biophysica Acta. 2006;1757(1):57-66
[86] Azekoshi Y, Yasu T, Watanabe 
S, Tagawa T, Abe S, Yamakawa 
K, et al. Free fatty acid causes 
leukocyte activation and resultant 
endothelial dysfunction through 
enhanced angiotensin II production in 
mononuclear and polymorphonuclear 
cells. Hypertension. 2010;56(1):136-142
[87] Shimokawa Y, Hirata K, Ishida 
T, Kojima Y, Inoue N, Quertermous 
T, et al. Increased expression of 
endothelial lipase in rat models of 
hypertension. Cardiovascular Research. 
2005;66(3):594-600
[88] Watanabe S, Tagawa T, Yamakawa 
K, Shimabukuro M, Ueda S. Inhibition 
of the renin-angiotensin system 
prevents free fatty acid-induced acute 
endothelial dysfunction in humans. 
Arteriosclerosis, Thrombosis, and 
Vascular Biology. 2005;25(11):2376-2380
[89] Leeman M, Lejeune P, Naeije R. 
Inhibition of angiotensin-converting 
enzyme by perindopril diacid in canine 
oleic acid pulmonary edema. Critical 
Care Medicine. 1987;15(6):567-573
[90] Bruce E, Shenoy V, 
Rathinasabapathy A, Espejo A, 
Horowitz A, Oswalt A, et al. Selective 
activation of angiotensin AT2 
receptors attenuates progression 
of pulmonary hypertension and 
inhibits cardiopulmonary fibrosis. 
British Journal of Pharmacology. 
2015;172(9):2219-2231
[91] Chuang EL, Miller FS, Kalina 
RE. Retinal lesions following long 
bone fractures. Ophthalmology. 
1985;92(3):370-374
[92] Lee JE, Jea SY, Oum BS, Kim 
HJ, Ohn YH. Effect of fat embolism 
with triolein emulsion on blood-
retinal barrier. Ophthalmic Research. 
2009;41(1):14-20
[93] Choudhary R, Kapoor MS, Singh 
A, Bodakhe SH. Therapeutic targets 
of renin-angiotensin system in 
ocular disorders. Journal of Current 
Ophthalmology. 2017;29(1):7-16
[94] Berlot G, Bussani R, Shafiei V, 
Zarrillo N. Fulminant cerebral fat 
embolism: Case description and review 
of the literature. Case Reports in Critical 
Care. 2018;7813175
[95] Jackson L, Eldahshan W, Fagan 
SC, Ergul A. Within the brain: The 
renin angiotensin system. International 
Journal of Molecular Sciences. 
2018;19(3):876-879
